NCT04105283 is a Phase 1 clinical trial of Tc99m-MAA in Lung Cancer, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04105283?

NCT04105283 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04105283?

Interventions in NCT04105283: Tc99m-MAA.

What condition does NCT04105283 study?

NCT04105283 studies Lung Cancer.

Is NCT04105283 still recruiting?

NCT04105283 is currently completed. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT04105283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning

Completed Phase 1 Last updated 15 October 2024

What this trial tests

Phase 1 trial testing Tc99m-MAA in Lung Cancer in 8 participants. Completed in 1 July 2024.

Timeline

1 August 2020

Primary endpoint
1 June 2024

1 July 2024

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	1 August 2020
Primary completion	1 June 2024
Estimated completion	1 July 2024
Sites	1 location across United States

Drugs / interventions tested

Tc99m-MAA — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study will evaluate the administration of a particle called macro-aggregated albumin (MAA) labelled with the radiotracer technetium 99m (Tc99m) as a proxy to estimate the anticipated dose of radiation to tumor and adjacent structures. Administration of this labeled MAA will not have a therapeutic benefit on the participant's cancer. Administration will help researchers determine if arterial administration of radiation may be feasible for lung cancer in the future.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

SPECT/CT Dosimetry of Bronchial Artery <sup>99m</sup>Tc Macroaggregated Albumin Injection in Pulmonary Malignancies: Feasibility Evaluation of Bronchial Artery <sup>90</sup>Y Radioembolization.
Wehrenberg-Klee E, An T, Heidari P, Huesa-Berral C, et al · · 2025 · cited 2× · PMID 39964268 · DOI 10.1148/radiol.240331

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04105283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04105283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing